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It has long been known that the synaptic vesicles of
certain glutamatergic terminals, as well as some in-
hibitory terminals, are richly supplied with zinc ions,
yet the functional role of this pool of zinc in synaptic
transmission has remained elusive. In this issue of
Neuron, Hirzel et al. provide direct in vivo evidence
that endogenous zinc is required for proper function-
ing of neuronal circuitry in the brainstem and spinal
cord. They show that knockin mice carrying a point
mutation which eliminates zinc potentiation of a1-
containing glycine receptors develop severe sensori-
motor deficits characteristic of impaired glycinergic
neurotransmission.
Zinc is an indispensable element in the molecular econ-
omy of all cells. While most zinc ions are trapped within
proteins, as structural or catalytic cofactors, in the brain,
there is a pool of zinc that is less tightly bound and that
can be revealed by histochemical techniques, such as
the Timm’s stain. The distribution of this potentially mo-
bilizable zinc is remarkable for two reasons: first, it is
mainly restricted to higher brain regions (viz. neocortex,
hippocampus, striatum, and amygdala); second, at the
ultrastructural level, histochemically reactive zinc is lo-
calized almost exclusively within synaptic vesicles of a
subset of glutamatergic axon terminals, where it is accu-
mulated by the vesicular zinc transporter ZnT3 (Freder-
ickson et al., 2005). However, there are notable excep-
tions to these rules since recently some staining of
‘‘chelatable’’ zinc has also been found in certain inhibi-
tory axon terminals of the cerebellum and spinal cord
(Danscher and Stoltenberg, 2005).
Most of the key players in fast synaptic transmission
are highly sensitive to extracellular zinc (Smart et al.,
2004; Frederickson et al., 2005). This is the case for
both the neurotransmitter receptors and transporters
of excitatory and inhibitory transmission and, depend-
ing on the nature of the target, zinc may either boost
or depress the synaptic response. Zinc is a potent inhib-
itor of NMDA and GABAA receptors as well as glutamate
and GABA transporters. In contrast, at glycine recep-
tors, zinc displays a biphasic effect, potentiating at sub-
micromolar concentrations and inhibiting at submilli-
molar concentrations.
The abundance of potential synaptic targets and the
location of zinc in synaptic vesicles all seem to point to
a role for zinc as a modulator of synaptic transmission
(Vogt et al., 2000). However, despite clear indications
that endogenous zinc is involved in excitotoxicity under
pathological conditions (Choi and Koh, 1998), there has
been no clear demonstration of a role for zinc in synaptic
transmission under physiological conditions. Moreover,
two recent findings have cast some doubt upon the
physiological relevance of zinc modulation. Knocking
out the ZnT3 gene leads to the total disappearance of
histochemical reactive zinc, yet results in no marked
phenotype other than a moderate increase in suscepti-
bility to epileptic seizures (Cole et al., 2000). Further-
more, whether zinc is indeed elevated in the synaptic
cleft during neuronal activity has been challenged byexperiments using zinc-sensitive fluorescent indicators,
which suggest that zinc may after exocytosis stick to the
presynaptic membrane and not diffuse freely in the cleft
(Kay, 2006).
In this context, the paper by Hirzel et al. (2006) (this
issue of Neuron), will certainly revive the flagging hopes
of zincologists. This work provides a clear demonstration
that interfering with zinc modulation of a synaptic path-
way leads to a significant alteration in the phenotype of
the animal. The authors used an original approach that
circumvents most of the bugaboos encountered in previ-
ous attempts to pin down the role of zinc. Rather than
modifying zinc levels with zinc chelators or genetic
manipulations, which necessarily produce pleiotropic
effects, Hirzel et al. (2006) chose to modify a specific syn-
aptic zinc target, the glycine receptor, which mediates
synaptic inhibition in the brainstem and spinal cord.
Given the strong association of zinc with glutamatergic
terminals, picking this particular target was risky, but Hir-
zel et al. (2006) clearly show that it paid off. The authors
produced a knockin (KI) mouse by introducing in the
gene coding for the murine a1 glycine receptor subunit
a point mutation (D80A) known from previous studies
on recombinant receptors to suppress high-affinity zinc
potentiation. Around P12, when the adult a1 GlyR sub-
unit replaces the neonatal a2 subunit, KI mice develop
both motor and sensory deficits typical of impaired glyci-
nergic transmission: inducible tremor, delayed righting
reflex, abnormal gait, increase in electroretinogram
b-wave amplitude, and an enhanced acoustic startle
response. This behavior is similar to a genetic disorder
in human infants termed hyperekplexia (startle disease),
which is characterized by an exaggerated startle reflex,
with ensuing stiffness and marked brainstem reflexes.
At the cellular level, the authors carefully verified that
the mutation selectively eliminated the high-affinity zinc
potentiation of glycine receptors without affecting their
glycine sensitivity, expression level, and synaptic tar-
geting. They further compared inhibitory transmission
in wild-type (WT) and KI animals by recording in brain
stem slices spontaneous IPSCs from hypoglossal moto-
neurons. The striking observation was that at P14–P16,
when a1 GlyR subunit dominates, both the IPSC ampli-
tude and decay are reduced in KI compared to WT ani-
mals. These results clearly indicate that in WT animals,
endogenous zinc effectively binds to and potentiates
synaptic glycine receptors by increasing receptor sensi-
tivity to the agonist. Undoubtedly this work is important,
since it directly demonstrates that zinc acts as an en-
dogenous modulator of synaptic transmission.
Exciting as these results are, there are of course many
questions that remain, e.g., how much zinc is seen by
the receptors. Does zinc act in a tonic or phasic fashion?
Where does it come from? Surprisingly, Hirzel et al.
(2006) found that application of exogenous zinc at
low mM concentrations to WT slices did not increase
the amplitude of glycinergic IPSCs, suggesting that in
slices the zinc potentiating site on GlyRs is persistently
saturated. Consistent with this interpretation, the au-
thors found that application of the chelator tricine de-
pressed the IPSCs in WT but not KI animals. However,
the authors’ conclusion that the levels of ambient zinc
are in the mM range is more questionable. This relies
on the estimated affinity of the zinc potentiating site on
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573Figure 1. Possible Mechanisms for Zinc
Modulation of Glycinergic NeurotransmissionGlyRs. Using buffered zinc solutions with controlled free
zinc concentrations, other groups have measured zinc
affinities of native and cloned glycine receptors more
than one order of magnitude higher than that reported
by Hirzel et al. (Suwa et al., 2001; Miller et al., 2005).
Therefore, synaptic zinc levels in the 10–100 nM range
may be sufficient to prevent potentiation by exoge-
nously applied zinc.
There are two ways in which we can imagine zinc
modulating synaptic transmission (see Figure 1). First,
phasically, where synaptic zinc diffuses freely into the
synaptic cleft after exocytosis and then binds to post-
or presynaptic receptors and transporters. Zinc modula-
tion would then wane rapidly as the zinc diffuses away
and is transported into cells. Second, tonically, where
zinc is bound to proteins within the synaptic vesicle
and is externalized on exocytosis but not much diffuses
into the cleft. Under this scenario, a few zinc ions could
be supplied to an extracellular layer of zinc, termed the
‘‘veneer’’ (Kay, 2006), where the metal stays associated
with proteins on the pre- and postsynaptic membranes,
including the neurotransmitter receptors. The degree of
tonic zinc modulation would be determined by the num-
ber of zinc ions in the veneer, which accumulate slowly
and progressively with synaptic activity and declines
as zinc is removed from the veneer. High enough tonic
zinc would explain the absence of effect seen by Hirzel
et al. (2006) upon application of exogenous zinc. How-
ever, these results are also compatible with a phasic
mechanism, assuming that during normal synaptic ac-
tivity zinc transiently reaches concentrations high
enough to saturate the GlyR zinc binding site. Thus,
whether the modulation occurs via the phasic rise of
zinc or through regulation of the tonic level of extracellu-
lar zinc remains wide open; clearly, more experiments
are needed. This question applies also to two other ma-
jor neurotransmitter receptors involved in fast neuro-
transmission, NMDA and GABAA receptors, since both
receptor families harbor zinc binding sites of high sensi-
tivity (nM affinity; Paoletti et al., 1997; Hosie et al., 2003).
What is the source of zinc at a glycinergic synapse?
One possibility could be that glycinergic presynaptic
vesicles accumulate zinc, as do glutamatergic and
some GABAergic terminals. Looking for ZnT3 expres-
sion in glycinergic neurons and analyzing zinc modula-
tion of glycinergic transmission in ZnT32/2 animals
should help clarify this point, although the fact that
ZnT3 KOs do not show hyperekplexia makes it unlikely
that ZnT3 loads vesicles associated with GlyR modula-tion. There is certainly no shortage of potential zinc
transporters that could do the job, as numerous genes
have been identified that code for proteins transporting
zinc into intracellular compartments (Palmiter and
Huang, 2004). Spillover of zinc from neighboring synap-
ses, likely glutamatergic, may provide an alternative
source of zinc (Kodirov et al., 2006, and see Figure 1).
The work of Hirzel et al. (2006) puts a nice dent in the
zinc armor, which held firm for more than 50 years, with
their demonstration that this ion acts as a physiologi-
cal neuromodulator of glycinergic transmission. Oddly
enough, zinc makes its debut as a synaptic neuromodu-
lator not at the zinc-enriched glutamatergic synapses of
the forebrain where one would have expected, but
rather at glycinergic synapses in the hindbrain. We
have little doubt that this initial success by inhibitory
‘‘outsiders’’ will trigger excitement in the glutamatergic
transmission field, where the paradox of the coexis-
tence of an activator (glutamate) and an inhibitor (zinc)
remains unsolved.
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as the SR proteins and members of the hnRNP group
of proteins (Black, 2003). Many more elements have
been identified, but their protein mediators are un-
known. Most alternative exons are controlled by multi-
ple splicing enhancer and silencer elements. Moreover,
many elements are not strict silencers or enhancers,
rather the position of an element relative to an alterna-
tive exon can determine whether it acts positively or
negatively (Hui et al., 2005). We need to know much
more about the rules that determine the positive or neg-
ative activity of these regulatory elements. What is the
code for exon use? What are the mechanisms by which
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Elements: Can We Predict the
Protein Output from an
Alternatively Spliced Locus?
Alternative splicing choices are governed by splicing
regulatory protein interactions with splicing silencer
and enhancer elements present in the pre-mRNA.
However, the prediction of these choices from geno-
mic sequence is difficult, in part because the regula-
tors can act as either enhancers or silencers. A recent
study describes how for a particular neuronal splicing
regulatory protein, Nova, the location of its binding
sites is highly predictive of the protein’s effect on an
exon’s splicing.
In eukaryotic cells, the formation of a mature mRNA re-
quires the removal of introns from the precursor mRNA
and splicing of its exons. This is a key step in determin-
ing the protein output from a gene. Alternative splicing
allows joining of exons in different patterns, enabling a
single gene to produce multiple protein isoforms (Black,
2003). This form of regulation is particularly common in
the mammalian nervous system where a large percent-
age (40%–60%) of neuronal pre-mRNAs undergo alter-
native splicing (Yeo et al., 2004). Many of these splicing
events produce proteins important for neuronal devel-
opment (e.g. neurexins, EphA7) and mature neuronal
function (e.g. NMDA receptor 1, CaV2), and changes in
the splicing of their pre-mRNAs result in multiple func-
tional variants (Lipscombe, 2005). A long-term goal of
genomic research is the prediction of the protein prod-
ucts of a gene under different cellular conditions. How-
ever, the frequency with which gene transcripts show al-
ternative splicing in the nervous system and the large
number of potential products from some of these genes
make this prediction extremely difficult.
The information that determines an alternative splic-
ing pattern is usually encoded within the sequence of
a regulated exon and its flanking introns in the form of
intronic or exonic splicing silencer elements (ISS or
ESS) and intronic or exonic splicing enhancer elements
(ISE or ESE). Enhancer elements promote the inclusion
of an exon, and silencers promote its skipping or exclu-
sion from the final mRNA. Many of these elements are
bound by known RNA-binding proteins (RBPs), such
these elements act on the splicing apparatus? A recent
paper in Nature shows for one splicing regulator that
such a code exists and can successfully predict the reg-
ulatory properties of the exon targets for this protein
(Ule et al., 2006). Moreover, this paper and recent
work from others have started to identify the specific
steps in spliceosome assembly affected by a regulatory
protein.
Genomic analyses of alternative splicing indicate that
the brain has the highest frequency of alternative splic-
ing (Sugnet et al., 2006; Yeo et al., 2004). The neuron-
specific inclusion or skipping of alternative exons is
primarily achieved by tissue-specific expression of par-
ticular RBPs (Matlin et al., 2005). Over a dozen neuron-
specific RBPs have been identified, including the Hu
family, members of the CELF family, neural PTB, the
Fox protein family, and Nova—the subject of the Nature
paper (McKee et al., 2005; Ule et al., 2006). These regu-
lators affect a wide range of target gene transcripts, en-
coding proteins involved in cytoskeletal rearrangement,
vesicular transport, cell adhesion, signal transduction
pathways, and synaptic activity (Lipscombe, 2005). In
earlier work, the Darnell lab identified Nova protein as
a YCAY element binding factor. They went on to use a va-
riety of biochemical, genomic, and genetic approaches
to identify a large number of exons in genes affecting
synaptic function whose splicing was affected by Nova
(Ule et al., 2006, and references therein).
The known Nova-regulated exons showed a variety of
dependencies, some enhanced by the protein and
others repressed. In the present study, the authors car-
ried out statistical analyses of the positions of YCAY
clusters relative to the known Nova target exons (Ule
et al., 2006). They noted the positions of these clusters
relative to the target exon and created a general map
relating the frequency of YCAY clusters surrounding
Nova-regulated exons. These clusters fall into relatively
few defined positions upstream, downstream, or within
the exon (Figure 1). Interestingly, certain positions
strongly correlate with splicing enhancement by Nova,
while other positions correlate with Nova acting to re-
press splicing. The authors tested the predictive value
of the map by searching a genomic database for addi-
tional YCAY cluster-containing exons that had not
been previously identified as Nova targets. The splicing
of these exons was compared in wild-type and Nova
knockout mice. They found that the positions of Nova-
dependent enhancers and silencers indicated by the
map were strongly predictive of the changes observed
between the presence and absence of Nova. This both
validated the value of the Nova RNA map and identified
a new set of Nova target exons.
